Mineralys' hypertension drug continues winning streak, lowering blood pressure in phase 2
Mineralys Therapeutics’ aldosterone synthase inhibitor has chalked up a third clinical win in recent months, demonstrating once again its potential to reduce blood pressure in patients with hypertension.
